- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01632995
Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics
Implementation of HIV Pre-exposure Prophylaxis (PrEP): A Demonstration Project
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A previous study (iPrEx) showed that daily PrEP with FTC/TDF provided with a comprehensive package of prevention services is effective in preventing HIV infection among men who have sex with men (MSM). The PrEP administered in that study was given in the context of a research setting/controlled trial, but it is important to evaluate the acceptability, sustainability, and safety of PrEP in a "real world" setting. This study will evaluate PrEP administered to HIV-uninfected MSM and transgender females at two STD clinics and one community health center in the United States.
Each participant will receive PrEP for up to 1 year and will have up to 8 study visits. PrEP will consist of one fixed-dose FTC/TDF combination tablet orally each day. All participants will have study visits at screening, enrollment, and 4 weeks after enrollment; participants will continue to have visits at Weeks 12, 24, 36, 48, and 52 if they do not seroconvert. Participants who seroconvert will discontinue PrEP and will have a post-drug discontinuation visit 4 weeks after discontinuing PrEP. At most visits, participants will undergo blood, urine, and hair sample collection; give a medical history; undergo a physical exam; receive risk-reduction counseling and condoms; undergo testing for HIV and other STDs; receive study drugs; and undergo a pill count and adherence assessment (follow-up visits only). For participants who stop taking the study drug but remain in the study, urine, blood, and hair samples will not be collected at 12-week follow-up visits if all stop procedures have been completed and if there are no lab abnormalities that require additional follow-up. Participants will also answer questionnaires at screening, 12-week visits, and at study exit.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94103
- SF City Clinic Non-Network CRS
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20009
- Whitman Walker Non-network CRS
-
-
Florida
-
Miami, Florida, United States, 33136
- Miami PrEP Non-Network CRS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be either a man who has sex with men or a transgender female
- Male sex (at birth)
- Willing and able to provide written informed consent
- HIV-1 uninfected, defined as having a negative rapid HIV antibody test at both screening visit and enrollment and a negative 4th generation antibody/antigen test at screening
- No laboratory evidence of a detectable HIV viral load (San Francisco site only)
Evidence of risk of acquiring HIV-1 infection including any one of the following:
(1) Condomless anal sex with two or more male or transgender female sex partners during the last 12 months; or (2) two or more episodes of anal sex with at least one HIV-positive partner during the last 12 months; or (3) sex with a male or transgender female partner and any of the following STDs diagnosed during the last 12 months or at screening: syphilis, rectal gonorrhea, or rectal chlamydia.
- Able to provide a street address of residence or phone number for themselves or two personal contacts who would know their whereabouts during the period of the demonstration project
- Adequate renal function: creatinine clearance of 60 ml/min or greater as estimated by the Cockcroft-Gault equation within 45 days of enrollment
- A urine dipstick with a negative or trace result for protein within 45 days of enrollment
- Fluent in English or in Spanish
Exclusion Criteria:
- Signs or symptoms of acute HIV infection
- Previously diagnosed active and serious infections including active tuberculosis infection or osteomyelitis and all infections requiring parenteral antibiotic therapy (other than STDs requiring intramuscular injections of antibiotics); active clinically significant medical problems including poorly controlled cardiac disease (e.g., symptoms of ischemia or congestive heart failure) or previously diagnosed malignancy expected to require further treatment
- Hepatitis B surface antigen (HBsAg) positive
- History of pathological bone fractures not related to trauma
- Receiving ongoing therapy with any of the following: investigational antiretroviral agents (PEP is allowed as described in the protocol), interferon (alpha, beta, or gamma) or interleukin (e.g., IL-2) therapy, agents with significant nephrotoxic potential, other agents that may inhibit or compete for elimination via active renal tubular secretion (e.g., probenecid), and/or other investigational agents
- Concomitant participation in a clinical trial using investigational agents, including placebo-controlled clinical trials using such agents
- At enrollment, has any other condition that, based on the opinion of the investigator or designee, would preclude provision of informed consent; make participation in the project unsafe; complicate interpretation of outcome data; or otherwise interfere with achieving the project objectives
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
|
Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of Acceptance Rate of PrEP
Time Frame: Measured through enrollment (Week 0)
|
Measured through enrollment (Week 0)
|
|
Measurement of Refusal Rate of PrEP
Time Frame: Measured through enrollment (Week 0)
|
Measured through enrollment (Week 0)
|
|
Duration of PrEP Use
Time Frame: Participants were followed for 48 weeks, or up to the point of early termination
|
Number of study drug interruptions
|
Participants were followed for 48 weeks, or up to the point of early termination
|
Duration of PrEP Use
Time Frame: Participants were followed for 48 weeks, or up to the point of early termination
|
Mean duration of interruptions
|
Participants were followed for 48 weeks, or up to the point of early termination
|
Measurement of Side Effects/Toxicities
Time Frame: Participants were followed for 48 weeks, or up to the point of early termination
|
Participants were followed for 48 weeks, or up to the point of early termination
|
|
Measurement of PrEP Adherence by TFV-DP Levels in DBS
Time Frame: Participants were followed for 48 weeks, or up to the point of early termination
|
Participants were followed for 48 weeks, or up to the point of early termination
|
|
Number of Male Sexual Partners
Time Frame: Participants were followed for 48 weeks, or up to the point of early termination
|
Participants were followed for 48 weeks, or up to the point of early termination
|
|
Measurement of PrEP Adherence by Medication Possession Ratio
Time Frame: Participants were followed for 48 weeks, or up to the point of early termination
|
Medication possession ratio is defined as the number of dispensed pills divided by the number of days between visits
|
Participants were followed for 48 weeks, or up to the point of early termination
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants Who Seroconvert
Time Frame: Participants were followed for 48 weeks, or up to the point of early termination
|
Participants were followed for 48 weeks, or up to the point of early termination
|
Measurement of HIV Drug Resistance Patterns Among Participants Who Become Infected
Time Frame: Participants were followed for 48 weeks, or up to the point of early termination
|
Participants were followed for 48 weeks, or up to the point of early termination
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Other Study ID Numbers
- PrEP Demonstration Project
- 11879 (Registry Identifier: DAIDS ES)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on FTC 200 mg/TDF 300 mg fixed-dose combination tablet
-
Gilead SciencesCompleted
-
ANRS, Emerging Infectious DiseasesGilead Sciences; Ministry of Health, Thailand; Assistance Publique - Hôpitaux... and other collaboratorsNot yet recruiting
-
Professor Francois VenterCompletedHIV-1 InfectionSouth Africa
-
Boehringer IngelheimCompletedHypertensionFrance, Switzerland, Italy, Germany, Hong Kong, Netherlands, South Africa, Spain, Taiwan, Denmark, Sweden, Finland, Ireland, Korea, Republic of, Malaysia, Norway
-
Columbia UniversityNational Institute of Mental Health (NIMH); Impact Research & Development OrganizationCompleted
-
Bristol-Myers SquibbCompletedHepatitis C Virus InfectionJapan
-
Kirby InstituteActive, not recruitingHIV InfectionsMalaysia, Zimbabwe, India, South Africa, Thailand
-
Merck Sharp & Dohme LLCCompleted